---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-024777"
form_type: "8-K"
ticker: "CRMD"
cik: "0001410098"
company_name: "CorMedix Inc."
filed_at: "2026-03-06T23:59:59+00:00"
generated_at: "2026-05-15T18:36:50.335825+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# CorMedix reaffirms FY2027 DefenCath guidance $100M-$140M; FY2026 revenue guidance $300M-$320M

## Summary
- Reaffirms FY2027 DefenCath sales $100M-$140M, correcting inadvertent $100M-$125M range from March 5 earnings call.
- FY2026 guidance: revenue $300M-$320M, adjusted EBITDA $100M-$125M, DefenCath sales $150M-$170M.
- Q4 2025 net revenue $129M, DefenCath sales $91M; FY2025 pro forma net revenue $401M.
- Pipeline milestones: REZZAYO prophylaxis Ph3 data expected Q2 2026; DefenCath TPN (NUTRI-LOCK) data 1H 2027.
- Balance sheet at Dec 31 2025: cash & short-term investments $149M, convertible debt $150M, shares outstanding 79.1M.

## SEC filing metadata
- accession: 0001213900-26-024777
- form_type: 8-K
- ticker: CRMD
- cik: 0001410098
- company_name: CorMedix Inc.
- filed_at: 2026-03-06T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1410098/000121390026024777/0001213900-26-024777-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1410098/000121390026024777/ea0280394-8k_cormedix.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-024777
- JSON: https://secwatch.observer/filing/0001213900-26-024777.json
- Plain text: https://secwatch.observer/filing/0001213900-26-024777.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.